Switch from Boosted PI to Maraviroc with Suppressed HIV MARCH
Study Design: MARCH

**Background:** Randomized, multicenter, open-label switch study

**Inclusion Criteria (n = 395)**
- HIV-1 infected adults
- R5-tropic HIV
- HIV RNA <200 copies/mL on stable (>24 weeks) 2 NRTI + boosted PI regimen
- Non-pregnant, not breastfeeding, no hepatitis B coinfection, no past virologic failure or resistance mutations

**Treatment Arms**
- Maraviroc + 2 NRTIs
- Maraviroc + Boosted PI + dual therapy
- Continue current ART

**Study Design:**

- **MVC + 2 NRTIs** (n = 156)
- **MVC + RTV-boosted PI dual ART** (n = 157)
- **Continue Current ART** (Control Arm) (n = 82)

Switch from Boosted PI to Maraviroc with Suppressed HIV MARCH: Results

Week 48 Results (Intention to Treat Analysis, ITT)

**Conclusions:** “These data support MVC as a switch option for ritonavir-boosted PIs when partnered with a 2-N(t)RTI backbone, but not as part of N(t)RTI-sparing regimens comprising MVC with PI/r.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*